Imeik Technology Development Co (300896) Q2 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was ¥1.30 billion, down 21.59% year-over-year; net profit attributable to shareholders was ¥789 million, down 29.57% year-over-year.

• Gross margin remained high, with core products maintaining strong market positions despite intensified competition and a slower industry growth rate.

• Completed the acquisition of Korea's REGEN Biotech, Inc., expanding international presence and product portfolio.

• Launched new products and advanced multiple R&D projects, with 22 new patent applications and several clinical and registration-stage pipeline products.

• Proposed a cash dividend of ¥12 per 10 shares, totaling ¥361.7 million, representing 45.82% of net profit.

Financial highlights

• Operating income: ¥1.30 billion, down 21.59% year-over-year.

• Net profit attributable to shareholders: ¥789 million, down 29.57% year-over-year.

• Operating cash flow: ¥655 million, down 43.06% year-over-year.

• Gross margin for core products remained above 93%.

• R&D investment reached ¥156.6 million, up 24.47% year-over-year, accounting for 12.05% of revenue.

Outlook and guidance

• The medical aesthetics industry is expected to maintain a ~10% CAGR through 2028, with non-surgical procedures leading growth.

• Company will continue to focus on product innovation, international expansion, and digital transformation of its marketing and service platforms.

• Ongoing R&D and new product launches are expected to support long-term growth and market leadership.